R&D Trends

Shire to acquire SARcode Bioscience, expand presence in ophthalmology

Monday, March 25, 2013 09:42 AM

Global specialty biopharmaceutical company Shire has agreed to acquire SARcode Bioscience, a Brisbane, Calif.-based privately held biopharmaceutical company. The acquisition continues to build Shire's presence in the ophthalmology therapeutic category and brings a new phase III compound—Lifitegrast—currently under development for the signs and symptoms of dry eye disease, into Shire's portfolio.

More... »

H3 Biomedicine, BGI Announce to develop, share cancer genomic sequencing data

Friday, March 22, 2013 03:33 PM

H3 Biomedicine, a biopharmaceutical company specializing in oncology treatments, and BGI, the largest genomics organization in the world, have entered into a partnership to sequence and publish genomic data from pre-clinical cancer models.

More... »

AstraZeneca, Moderna Therapeutics to develop pioneering messenger RNA Therapeutics

Friday, March 22, 2013 10:51 AM

AstraZeneca, a global biopharmaceutical company, has formed an exclusive agreement with Moderna Therapeutics, a Cambridge-Mass.-based biopharmaceutical company, to discover, develop and commercialize pioneering messenger RNA therapeutics for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer.

More... »

bluebird bio collaborates with Celgene to advance gene therapy in oncology

Friday, March 22, 2013 10:23 AM

bluebird bio, a Cambridge-Mass.-based privately-held biotechnology company focused on gene therapy, has formed a broad, global strategic collaboration with Celgene, a Summit, N.J.-based integrated global biopharmaceutical company focused on cancer and inflammatory diseases, to discover, develop and commercialize novel disease-altering gene therapies in oncology.

More... »

Malaysian Bio-XCell, Agila Biotech ink $34M Build-and-Lease Agreement

Wednesday, March 20, 2013 10:37 AM

Malaysian Bio-XCell and Agila Biotech signed a $34.4 million Build-and-Lease Agreement for the establishment of a customized biotech facility located in the Bio-XCell biotechnology park and ecosystem in Nusajaya, Malaysia.

More... »

Wilex, Nuclea Biotechnologies form partnership

Wednesday, March 20, 2013 10:08 AM

Pittsfield, Mass-based biomarker pioneer Nuclea Biotechnologies has formed a new long-term partnership with biopharmaceutical company Wilex, which could lead to more effective treatment management for women with metastatic breast cancer. The partnership aims to advance R&D of biomarkers, a vital component in the growing field of personalized medicine. 

More... »

Scripps Research, Takeda expand research collaboration

Wednesday, March 20, 2013 09:11 AM

The Scripps Research Institute (TSRI), an independent, not-for-profit organization focusing on research in the biomedical sciences, and Takeda Pharmaceutical, a research-based global pharmaceutical company, plan to expand their recent research collaboration to search for new drug targets for a variety of diseases.

More... »

New Alzheimer’s Association report reveals one in three seniors dies with dementia

Tuesday, March 19, 2013 03:32 PM

According to the Alzheimer's Association’s just released 2013 Alzheimer's Disease Facts and Figures report, one in three U.S. seniors dies with Alzheimer’s or another dementia.

More... »

U.K.’s Technology Strategy Board and Indian government sign program of co-operation

Tuesday, March 19, 2013 11:30 AM

The Technology Strategy Board (TSB) and the Indian government’s Department of Science and Technology have agreed to undertake a joint program to support innovative U.K. and Indian businesses working together on the commercialization of research in a range of key areas, including energy and healthcare. The ‘Program of Co-operation’ was signed at an international reception held at the InnovateUK conference in London.

More... »

Avitide secures Series A financing for novel affinity purification tech

Monday, March 18, 2013 11:17 AM

Avitide, a biotech company dedicated to the discovery and development of custom affinity purification solutions, announced the closing of their Series A financing. The Avitide technology is designed to discover and develop affinity purification products that will improve the fundamental timeframes and economics of commercial bioprocessing.

More... »